Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)
Clinical trial NCT04644029 · TERMINATED
Trial details
- NCT number
- NCT04644029
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-02-24
- Primary completion
- 2023-07-18
- Enrollment
- 730
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.